Renaissance Technologies’s Tarsus Pharmaceuticals TARS Stock Holding History

Renaissance Technologies’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$585K	Sell	9,300 -64,100	-87%	-$4.1M	﹤0.01%	2545
2026 Q1	$5.15M	Buy	73,400 +9,300	+15%	+$650K	0.01%	1366
2025 Q4	$5.25M	Buy	64,100 +22,500	+54%	+$1.68M	0.01%	1275
2025 Q3	$2.47M	Buy	+41,600	New	+$2.05M	﹤0.01%	1930
2023 Q4	–	Sell	-106,900	Closed	-$1.9M	–	4124
2023 Q3	$1.9M	Sell	106,900 -7,600	-7%	-$134K	﹤0.01%	1900
2023 Q2	$2.07M	Buy	114,500 +40,500	+55%	+$644K	﹤0.01%	1975
2023 Q1	$930K	Buy	74,000 +8,400	+13%	+$123K	﹤0.01%	2524
2022 Q4	$962K	Sell	65,600 -3,900	-6%	-$64.5K	﹤0.01%	2557
2022 Q3	$1.19M	Buy	69,500 +9,200	+15%	+$146K	﹤0.01%	2390
2022 Q2	$880K	Buy	+60,300	New	+$905K	﹤0.01%	2798

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies's TARS Position: Q2 2026 in Review

Renaissance Technologies reduced its Tarsus Pharmaceuticals (TARS) stake by 87% in Q2 2026, selling an estimated $4.1M and leaving 9,300 shares worth $585K. The position accounts for ﹤0.01% of the portfolio, ranked #2545.

Renaissance Technologies first reported a position in TARS in Q2 2022 and has held it in 10 quarters since. The position peaked at $5.25M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Renaissance Technologies held 9,300 shares of Tarsus Pharmaceuticals worth $585K as of Q2 2026.
Renaissance Technologies sold 64,100 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $4.1M.
Tarsus Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2545 holding.
Renaissance Technologies first reported a position in Tarsus Pharmaceuticals in Q2 2022 and has held it in 10 quarters since.
Renaissance Technologies's Tarsus Pharmaceuticals position peaked at $5.25M in Q4 2025.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.